Dew,
Do you think Boceprevir will get rejected? After reading thru the all the HCV posts, it seems like MRK took a shortcut with their def. of null responder, which could come back to haunt them if the advisory panel and folks at the FDA make a stink about it. Based on the Telaprevir data, one could envision the FDA approving Telaprevir and rejecting Boceprevir in the meantime. There's no rush to have 2 new treatments, especially if one of them has some potentially biased data because of the null responder definition.
Market Data 
Markets 
AI
